ARKG – ARK Genomic Revolution ETF
ARK Genomic Revolution ETF (ARKG) is a Health ETF, issued by ARK ETF Trust, $2.2B in assets, 0.71% expense ratio.
Returns as of Oct 23, 2026: 1 week +3.1%, 1 year +45.0%.
Actively-managed fund investing in companies across multiple sectors relevant to the genomics revolution, focusing on healthcare and technology.
Top holdings
- TXG – 10X Genomics Inc, 8.8%
- TEM – Tempus AI, Inc. Class A Common Stock, 8.2%
- TWST – Twist Bioscience Corp, 7.8%
- CRSP – Crispr Therapeutics AG, 5.6%
- NTRA – Natera Inc, 5.1%
- ILMN – Illumina Inc, 5.0%
- GH – Guardant Health Inc, 5.0%
- ABSI – Absci Corp, 4.6%
- LLY – Eli Lilly and Company, 4.3%
- CDNA – CareDx Inc, 3.9%
- BEAM – Beam Therapeutics Inc, 3.4%
- VCYT – Veracyte Inc, 3.3%
- CMPS – Compass Pathways Plc, 2.9%
- NRIX – Nurix Therapeutics Inc, 2.8%
- RXRX – Recursion Pharmaceuticals Inc, 2.6%
- SDGR – Schrodinger Inc, 2.6%
- ADPT – Adaptive Biotechnologies Corp, 2.2%
- NTLA – Intellia Therapeutics Inc, 2.0%
- IONS – Ionis Pharmaceuticals Inc, 2.0%
- WGS – GeneDx Holdings Corp., 1.8%
- BFLY – Butterfly Network Inc, 1.7%
- ALMR – Alamar Biosciences, Inc. Common Stock, 1.6%
- PRME – Prime Medicine, Inc. Common Stock, 1.5%
- ARCT – Arcturus Therapeutics Holdings Inc, 1.5%
- MASS – 908 Devices Inc, 1.2%